Literature DB >> 449915

Immune interferon in the circulation of patients with autoimmune disease.

J J Hooks, H M Moutsopoulos, S A Geis, N I Stahl, J L Decker, A L Notkins.   

Abstract

The observation that type II, or immune, interferon could be produced by peripheral-blood leukocytes in vitro on an immune-specific basis suggested that it also might be produced in vivo in various autoimmune disorders. We found immune interferon in the serums of patients with systemic lupus erythematosus, rheumatoid arthritis, scleroderma and Sjögren's syndrome. Among 28 patients with systemic lupus erythematosus, 71 per cent of those with active and 21 per cent of those with inactive disease showed interferon in their serums. Serial serum samples showed a good correlation between interferon titers and disease activity. Moreover, interferon titers correlated positively with antibodies to DNA and negatively with serum levels of the third component of complement. It is possible that the production of interferon may contribute to immunologic aberrations in auto-immune diseases and also protect the already compromised host from viral infections.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 449915     DOI: 10.1056/NEJM197907053010102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  295 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

3.  Evidence against an autoimmune aetiology for inflammatory bowel diseases.

Authors:  F Pallone; S Fais; M R Capobianchi
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 4.  Impaired clearance of apoptotic cells in germinal centers: implications for loss of B cell tolerance and induction of autoimmunity.

Authors:  Ziaur S M Rahman
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

5.  Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients.

Authors:  Rafah Salloum; Beverly S Franek; Silvia N Kariuki; Lesley Rhee; Rachel A Mikolaitis; Meenakshi Jolly; Tammy O Utset; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2010-02

6.  Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus.

Authors:  Di Feng; Rivka C Stone; Maija-Leena Eloranta; Niquiche Sangster-Guity; Gunnel Nordmark; Snaevar Sigurdsson; Chuan Wang; Gunnar Alm; Ann-Christine Syvänen; Lars Rönnblom; Betsy J Barnes
Journal:  Arthritis Rheum       Date:  2010-02

7.  Presence of interferon and anti-interferon in patients with systemic lupus erythematosus.

Authors:  P von Wussow; D Jakschies; K Hartung; H Deicher
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

8.  Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway.

Authors:  N C Kyriakidis; E K Kapsogeorgou; V C Gourzi; O D Konsta; G E Baltatzis; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

9.  Spontaneous production of human gamma interferon in vitro by splenic lymphocytes of patients with idiopathic thrombocytopenic purpura.

Authors:  Y W Hu; G X Xue; Y H Tan
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

10.  Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis.

Authors:  William R Lagor; David W Fields; Robert C Bauer; Alison Crawford; Michael C Abt; David Artis; E John Wherry; Daniel J Rader
Journal:  Atherosclerosis       Date:  2014-01-10       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.